Yamirka Sanchez Perez
General Practice · Miami, FLNPI 1346741618
Payments from drug & device makers
Across 330 payments — averaging $2765.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$794K
- Novo Nordisk AS$81K
- Lexicon Pharmaceuticals, Inc.$27K
- Teva Pharmaceuticals USA, Inc.$9K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Novo Nordisk$24
- plus $59 from 3 others
Across 11 payments — averaging $124.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1K
What the payments were for
- Food & beverage$83100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $793,860 |
| Novo Nordisk AS | 207 | $81,059 |
| Lexicon Pharmaceuticals, Inc. | 7 | $26,997 |
| Teva Pharmaceuticals USA, Inc. | 1 | $8,820 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $1,900 |
| Novo Nordisk | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| AstraZeneca | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$912,718 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $153,927 |
| JanuviaSitagliptin Phosphate | 107 | $125,359 |
| EntrestoSacubitril/Valsartan | 60 | $58,191 |
| FarxigaDapagliflozin Propanediol | 50 | $42,046 |
| JardianceEmpagliflozin | 23 | $38,773 |
| XareltoRivaroxaban | 28 | $35,085 |
| OzempicSemaglutide | 21 | $19,132 |
| TrulicityDulaglutide | 12 | $16,949 |
| Atrovent HfaIpratropium Bromide | 27 | $15,048 |
| LinzessLinaclotide | 14 | $13,997 |
| MounjaroTirzepatide | 12 | $12,621 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $11,387 |
| BrilintaTicagrelor | 13 | $8,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,113 |
| LumiganBimatoprost | 16 | $7,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $21 | $50,29363 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $16 | $29,57124 claims |
| Novo NordiskOzempic, Novolog, Novolog Mix 70-30 | $24 | $24,16447 claims |
| GSKTrelegy Ellipta | $793,860 | $8,11313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Miami
- Jose CardonaMiami$71M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Hector RodriguezMiami$12.8M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Omar BenitezMiami$6.9M
- Sara LlerenaMiami$6.3M
- Ana AcostaMiami$6.3M
- Gil Fernandez-YeraMiami$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.